Continuing Education Activity

Urge incontinence is a type of urinary incontinence in adults, which involves sudden compelling urges to void and results in involuntary leakage of urine. This is a serious and debilitating condition and has a social stigma attached to it. To avoid the huge socioeconomic burden and high morbidity associated with this condition, early diagnosis, treatment, and referral concepts must be widely practiced among clinicians. This activity reviews the evaluation and management of urge incontinence and highlights the role of the interprofessional team in improving care for patients with this condition.

Objectives:

• Describe the typical presentation of a patient with urge incontinence.
• Outline how to evaluate and differentiate urge incontinence from other conditions.
• Summarize the management considerations for urge incontinence.
• Identify the importance of collaboration amongst the interprofessional team to enhance the delivery of care for patients affected by urge incontinence.

Introduction

Urinary incontinence is known as the leakage of any volume of urine, which is mostly involuntary. The three most well-known types of urinary incontinence are urgency/urge incontinence, stress incontinence, and overflow incontinence. Some patients have symptoms of many different types (mixed), and some can have functional symptoms.[1] Patients with urge incontinence typically complain of a sudden compelling urge to void that is difficult to hold and that often results in involuntary leakage of urine.[2][3] 

Stress incontinence involves involuntary, often sudden, loss of urine due to increased intra-abdominal pressure. On the other hand, overflow incontinence mainly includes an overdistended bladder (either due to reduced detrusor contractility and/or bladder outlet obstruction), often leading to involuntary loss of urine. This article will be focusing on a brief review of urgency/urge urinary incontinence.

Etiology

The etiologies of urge incontinence often involve the detrusor muscle of the urinary bladder, which is the specialized smooth muscle in the bladder wall. These include detrusor muscle overactivity, poor compliance of the detrusor, and bladder hypersensitivity.

• Detrusor overactivity is believed to be the uninhibited (involuntary) contractions of the smooth muscle during bladder filling. Significant causes leading to this overactivity could be neurologic disorders (spinal cord injury), abnormalities in the urinary bladder, and an increase or alteration in the bladder microbiome.[4][5][6] This may also be completely idiopathic.[7]
• Poor detrusor compliance results in the failure of the bladder to stretch and thereby increase in intravesicular pressure. It also involves discomfort during filling and limited capacity. Pelvic radiotherapy or prolonged periods of catheterization can often lead to this.
• Bladder hypersensitivity and the sensory role of the urothelium are believed to be intertwined. It has recently been established that as the urothelium acts as a pivotal mediator of bladder function, the role of urothelial inflammation and infection can lead to the overactive bladder with or without urgency.[8] Here again, the balance of urinary microbiota can alter bladder function, sensation, and, perhaps, lead to urgency incontinence.[9]

Epidemiology

The prevalence of urinary incontinence of any kind varies mainly with age and obesity. Other factors found to be associated with urinary incontinence of different subtypes include previous hysterectomy or pelvic surgery, parity, pulmonary disease, diabetes mellitus, dementia, or residing in a nursing home.[10][11][12][13]

The data regarding the true prevalence of different types of urinary incontinences vary widely depending on the population studied, the social stigma and lack of interest to self-report (respondent bias in observational studies), and also on the case definitions in the questionnaires used.[2] This is probably the reason why, in many epidemiological studies from earlier dates, there had been no differentiation between urge and stress urinary incontinence.

Accurate prevalence measurement for urinary incontinence via robust epidemiological studies and validated measures tend to exist more in the United States and some developed European /Asian countries rather than the developing world. Even then, the reported prevalence for any sub-type of urinary incontinence in adult women is of a broad range (5% to 72%), with an approximate convergence of 30% according to different studies).

Overall, the association of age and urinary incontinence is well established. When the whole population is considered as one, most studies pick either mixed or urge incontinence as less prevalent than stress incontinence.[12] Observational data from four European countries, as well as median prevalence data from a review of epidemiological studies from around the world, have revealed similar trends. Unlike stress incontinence, which reaches a peak mostly around the fifth decade of a patient's life and then shows a decline, both urge, and mixed incontinence continues to increase in prevalence with increasing age.[10][14] The association of age with incontinence also prevails in men, but severe incontinence in elderly males is often half the number of that in women.[10][15]

When considering the prevalence of urge incontinence specifically among women and men, a slightly different picture is depicted. Studies have shown that stress incontinence is of high prevalence among postmenopausal women, whereas urge incontinence may have a somewhat lower prevalence. Even then, it is this second type of incontinence that is often extraordinarily bothersome and is more likely to require treatment.[15] The prevalence of "any sub-type" of urinary incontinence" (3% to 11%) in all ages of men is considered much lower than that for women. Interestingly, urge incontinence is often the predominant subtype among 40% to 80% of those within the male population.[16]

History and Physical

The care for any urinary incontinence almost always begins at a primary clinician’s office. The presentation of incontinence symptoms can often be late due to the unwillingness of the patient population to report it. Therefore, a thorough and empathetic history taking should be conducted by the primary clinician. History should include discussion about the patient’s typical voiding pattern, onset, and duration of incontinence symptoms, whether or not the patient is bothered by symptoms and any associated factors that can affect incontinence, i.e., amount and type of daily fluid intake and bladder irritants (caffeine, carbonated beverages, artificial sweeteners, alcohol, etc.). Most histories should also focus on triggering factors or events of urinary incontinence (e.g., feeling of urgency, cough, sneezing, feeling of running water, lifting, bending, sexual activity, movement, changes in position), constant or intermittent leakage of urine, coexisting medical condition (such as diabetes mellitus, diabetes insipidus, urogynecological cancer, cardiorespiratory diseases, chronic cough, dementia, delirium, presence of a urinary tract infection, obesity and sleep apnea). 

Other factors requiring assessment should include urinary frequency (>7 micturition episodes in a day), urgency, pain with a full bladder, obstetric history (number and mode of deliveries), gynecological history (history of pelvic organ prolapse, anal incompetence, menopause, sexual dysfunction), any previous pelvic surgery (incontinence procedures, pelvic floor reconstruction, and hysterectomy), history of surgery of the central nervous system or spinal surgeries.[17] 

Clinicians should also do a thorough review of any current medicines that can exacerbate or lead to incontinence symptoms, e.g., alpha-adrenergic agonists and antagonists, angiotensin-converting enzyme (ACE) inhibitors, anticholinergic drugs, calcium channel blockers, cholinesterase inhibitors (increases bladder contractility and can cause urgency incontinence), diuretics, lithium, psychotropic medications, sedatives, hypnotics, selective serotonin reuptake inhibitors (the increased cholinergic activity can lead to urge incontinence) and lastly opioid analgesics.[8]

It is well validated that sometimes symptom presentation is not enough to guide patient care for a specific type of urinary incontinence. A focused physical examination, therefore, should include pelvic/genitourinary examination as well as neurological, gait, mental status, and body mass index (BMI) assessment, all of which can be started in the primary care setting. An abdominal examination can reveal information regarding any costovertebral angle tenderness, pelvic masses, and palpable bladder. A positive Valsalva maneuver for >6 seconds might reveal evidence of pelvic organ prolapse. A digital examination of the pelvic floor will disclose information regarding the tone and strength of the pelvic floor. Additionally, a speculum exam might reveal vaginal atrophy, incontinence associated dermatitis, and extra-urethral urine loss/fistula.[8] 

Neurological examination should include details of mental status, perineal reflexes and sensation, patellar reflexes, gait, and a mobility assessment.[18] A postvoid residual gives valuable insight to bladder emptying in patients with obstructive symptoms or neurological diseases but should only be done with ultrasonography for better accuracy and less invasiveness.[17][19] Congestive heart failure should also be ruled out with a cardiovascular examination in case of any lower extremity edema.[18]

While it is challenging to not have a single test to diagnose urge incontinence, other simple office-based examinations can aid in ruling out different types and pathophysiology of incontinence. A positive cough stress test (observation of immediate leakage of urine with cough when a bladder has at least 200 mL of urine) has excellent sensitivity and specificity for stress incontinence, especially in standing position. A cotton swab test can be used to evaluate urethral hypermobility. Here a cotton swab is inserted through a lubricated urethra up to the neck of the bladder, and the test is considered positive if the cotton swab angle changes >30 degrees from resting position with the Valsalva maneuver.[19]

Evaluation

The evaluation for urge incontinence of urine can be done with the following sequential steps.

1. The first step should always involve a thorough history and physical examination. At this stage, some validated questionnaires can also be used. Commonly used questionnaires to quantify the amount of bother, and bladder symptoms include the short form of Pelvic Floor Distress Inventory and the short form Pelvic Floor Impact Questionnaire.[20] These questionnaires evaluate bladder symptoms, pelvic organ prolapse symptoms, and any bowel symptoms. While the Pelvic Floor Distress Inventory weighs the measure of severity, the Pelvic Floor Impact Questionnaire assesses the impact of these symptoms on a person's social functioning and the activities of daily living. Other questionnaires that are recommended by The International Consultations on Incontinence are the Urogenital Distress Inventory (UDI), King's Health Questionnaire, Urge UDI, etc.[21]
2. The second step can include urine analysis with microscopy and, if needed, culture to rule out any hematuria, glycosuria, and urinary tract infection (UTI). At this time, office-based examinations like a cough stress test, cotton swab test, post-void residue, and voiding diary can be utilized. A voiding diary can clarify fluid intake, symptoms, and situations in which the incontinence symptoms occur.[22]
3. Anytime during these steps, assessment should also aim to rule out reversible causes. Decisions should also be made when to refer to a urologist/urogynecologist. The reversible causes can be memorized with the mnemonic DIPPERS (delirium, infection, pharmaceutical, psychological morbidity, excess fluid intake, restricted mobility, and stool impaction). If present, any of these conditions need treatment and reassessment. Referral to a specialist should be considered if there is bladder pain, advanced urological prolapse, fistula, neurological symptoms, urogenital malignancy, urogenital surgery, recurrent UTI, sterile pyuria, hematuria, post-void residual volume of more than 50 mL, and insensible loss of urine.[8]
4. The third step is to try to decide the presumed type of urinary incontinence from the information gathered. Points in favor of urge incontinence include symptoms of urgency, typical frequency and nocturia, no incontinence with cough, sneezing, lifting, position change, variable volume loss on voiding diary, negative cough stress test, and post-void residual volume of < 50 mL.
5. The final step involves the utilization of urodynamic studies. These studies can acquire valuable information about the relationship of pressure and flow between the urethra and the bladder. They also often provide ample details on lower urinary tract function. Even though these studies are outside the scope of primary clinicians' office, they can be crucial to achieving a correct diagnosis of mixed and urge incontinence.[23] Indications for these urodynamic studies are:

   • Significant inconsistencies between symptom scale, history, and voiding diary
   • Planned or previous surgery
   • Hematuria
   • The presence of neurological diagnoses such as multiple sclerosis
   • Associated prolapse of pelvic organs
   • Previous history of correction surgery for incontinence
   • Elevated volume of post-void residual urine.
   • Well known components of urodynamic studies include a) uroflowmetry, b) cystometry, c) post-void residual urine volume, d) urethral pressure profiles for urethral closure pressures, e) leak point pressure measurement, f) neurophysiologic studies.[18]

Treatment / Management

The treatment of urge urinary incontinence is designed to achieve a degree of decrease in bladder contractility. It also aims to acquire increased bladder capacity and decreased afferent input to the bladder.[3] According to the American Urological Association guidelines, treatment options should be considered at three different levels.

• The first-line treatment includes teaching the patient some behavioral therapies such as bladder training and toileting habits, lifestyle modifications, voiding diary, dietary changes, and avoiding bladder irritants (such as caffeine, smoking), pelvic floor muscle training (PFMT), and biofeedback.
• The second-line treatment option includes the use of medications, namely antimuscarinic and beta 3 agonist therapy.

  1. Some antimuscarinic agents currently available for the treatment of urge incontinence include oxybutynin, tolterodine, fesoterodine, trospium, darifenacin, and solifenacin. At present, no substantial evidence exists for the most efficacious antimuscarinic drug. Extended-release versions have been found to cause lesser side effects compared to immediate-release versions.[24] The common side effects related to these drugs are dry mouth, blurred vision, tachycardia, constipation, impaired cognition, and urinary retention. These side effect profiles have often culminated in high discontinuation rates and less than standard compliance rates.[17] Medicines like darifenacin and solifenacin (selective antimuscarinic agents) are sometimes preferred over non-selective agents to control cognitive side effects better.[25]
  2. The beta-3 adrenoreceptor agonists cause direct relaxation of detrusor muscles. They achieve inhibition of spontaneous contractile activity in the bladder and reduction in bladder afferent activity. Mirabegron is the first of its class and the only beta-3 adrenoceptor agonist that is used as a second-line treatment for those who either poorly tolerate antimuscarinic agents or cannot tolerate them at all. Daily doses of mirabegron 25, 50, and 100 mg demonstrated significant efficacy in treating symptoms of urge incontinence in phase three clinical trials.[26] In some cases, combining an anticholinergic medication with mirabegron may result in increased efficacy and minimized side effect load.[27] This medication can theoretically lead to an increase in cardiovascular events, particularly hypertension and headaches.
• If patients with urge incontinence meet the following criteria, they are eligible for third-line treatment (refractory cases): 1) They demonstrate a failure of response to behavioral therapy, and 2) They have either intolerance to or inadequate response to at least two second-line treatments. Third-line treatment includes the three following unique types of neuromodulations that are FDA approved: Percutaneous stimulation of tibial nerve (PTNS), temporary chemical denervation of the bladder detrusor muscle, and sacral neuromodulation. PTNS involves weekly sessions for the initial three months and then monthly maintenance treatments. Contraindications to PTNS should be carefully assessed, which include patients with pacemakers/defibrillators, nerve damage involving tibial nerve or pelvic floor function, and patients that are pregnant.[17] Intravesical onabotulinum toxin A injection is also approved by the FDA and requires delivery via cystoscopy every six months if symptoms recur. It results in flaccid paralysis of the detrusor muscle with consistent improvement in urge incontinence symptoms and quality of life. Other neuromodulations such as sacral, pudendal, and paraurethral nerve stimulators can be surgically implanted. Intra-vesicular onabotulinum toxin A injection was shown to be superior to neuromodulation devices for the reduction of urgency symptoms in a 2016 study.[25]

Differential Diagnosis

The differential diagnoses for urge incontinence include all of the reversible causes discussed in the evaluation section. Then again, the classification and characterization of urinary incontinence are somewhat challenging. It is most often dependent on history and subjective complaints from the patient due to a lack of adherence to proper history and physical exam technics. Therefore urge incontinence symptoms can easily have a differential diagnosis of either stress or mixed type incontinence. Another more common differential diagnosis can be overactive bladder syndrome (OAB). While urge incontinence and OAB are often used interchangeably, most OAB cases do not have any incontinence symptoms. Other conditions, such as diabetes mellitus, recurrent UTI, and neurological diseases, can also be included in the differential diagnosis for the urge incontinence.

Prognosis

The prognosis of urge incontinence differs from person to person, and hence treatment plans should ideally be individualized after discussion with the patient. While behavioral therapy and medications have promising results in the younger patient population, the options of neuromodulation should be considered early in the algorithm for the elderly population. According to the American Urological Association, the efficacy of treatment guidelines and prognosis of urge urinary incontinence depends on many factors related to the patient's age and co-morbid conditions. Frailty, functional and cognitive impairment, family/caregiver support, co-morbid conditions play pivotal roles in a patient's participation in behavioral therapies. Comparatively, younger individuals have a higher success rate and increased quality of life with behavioral therapies alone or combined with medications.

The use of antimuscarinic agents in elderly patients with cognitive impairment and dementia might lead to further worsening of dementia/Alzheimers disease. Coexisting medications with anticholinergic properties such as medications for parkinsonism, donepezil, anti-nausea medications, and sedatives will lead to poor prognosis. Thus third-line treatment options such as PTNS might need to be included in treatment and prognosis discussion earlier in the disease process for the elderly/affected population. A baseline mini-mental status exam score can prove vital while assessing the quality of life improvement. Beer's criteria for risk assessment or antimuscarinic risk scale can be considered essential for the elderly population, whereas, in the younger community, side effect management can lead to better disease prognosis and treatment success.[28] 

Again, while considering the third-line treatment options, cognitive assessment is essential to predict the outcome. Despite all these considerations, when left untreated or unattended, the prognosis of urge urinary incontinence is abysmal. It is socially burdensome and leads to significant morbidity.

Complications

Complications of urge urinary incontinence can be related to the disease process itself and also to the medications and surgical procedures.[29] Complications of chronic urinary incontinence include:

• Skin problems including dermatitis/rashes and bedsores from prolonged periods of wet skin
• Recurrent urinary tract infections
• Progressive cognitive impairment from the use of different anti-muscarinic agents
• Significant impact on the quality of life and loss of independence in performing activities of daily living

Complications of all the surgical or bladder neuromodulation procedures can be:

• Injury to the genitourinary tract
• Chronic catheterization
• Persistent or recurrent urinary incontinence

Deterrence and Patient Education

Despite the wide prevalence of urge incontinence, very few patients seek help, assuming that they just have to live with it. Specific questions for urinary symptoms of urge and stress incontinence should be included in the review of systems, as many patients are uncomfortable discussing this with the provider. When history and exam are suggestive of urge incontinence, lifestyle changes like cutting back on caffeine, alcohol, artificial sweeteners that increase urinary frequency and avoiding them close to bedtime can help many patients to reduce urgency and urine leaks. It is important to avoid constipation that could worsen urge incontinence by increasing fiber intake. Even though many patients have heard about pelvic floor exercises and bladder retraining, they often perform them incorrectly. Providers should take the opportunity during the initial evaluation to educate on the correct technique of the exercises or offer a referral to a physical therapist who has special training in these exercises.

Asking the patient to have scheduled bathroom breaks helps to retrain the bladder. To begin, the patient should be asked to hold their urine for at least an hour. If they feel the urge, ask them to try to wait until the whole hour is passed. After they get used to waiting 1 hour, the patient can try waiting longer between bathroom visits. The goal should be to train the bladder to hold urine for 3 to 4 hours between bathroom visits. During an urge, patients can try sitting down or standing still, taking a deep breath, and squeeze the pelvic floor muscles. This can help them relax and overcome the urge. When the urge passes, they can then walk slowly to the bathroom to urinate. 

Providing printed handouts and going through self-management skills and outlining the available treatments to control and cope with the symptoms will improve patient confidence and cooperation with the treatment. Resourceful patient education is available on the American College of Obstetrics and Gynecology website.

Enhancing Healthcare Team Outcomes

Urge incontinence is a complicated condition, and patients often present late to their primary care providers. Therefore, primary care providers should be proactive in gathering a thorough history, physical examination, perform office-based investigations to rule out reversible causes, and decide when to refer to a specialist (urologist/urogynecologist). A culture of shared and informed decision making with the patient should be developed. In this process, patients and their family members or caregivers should also be included. A clear cut discussion on the treatment goal and different treatment options often leads to better patient compliance.

A thorough review of all possible reasons for the failure of treatment, side effects of various medications, and measures of improvement of quality of life should also be included. For example, not all patients will achieve complete incontinence free life. Still, many will see a significant reduction in bothersome symptoms that might lead to a considerable improvement in the quality of life. The ethical responsibility of the clinician is to always offer the least invasive treatment option depending on the patient's co-morbidities. An interprofessional team approach involving excellent communication among specialists, primary care providers, patients/families, nurses, and pharmacists often leads to improved treatment outcomes, patient-centered care, and better patient safety.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Holroyd-Leduc JM, Tannenbaum C, Thorpe KE, Straus SE. What type of urinary incontinence does this woman have? JAMA. 2008 Mar 26;299(12):1446-56. [PubMed: 18364487]

2.

Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN., International Urogynecological Association. International Continence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4-20. [PubMed: 19941278]

3.

Chung E, Katz DJ, Love C. Adult male stress and urge urinary incontinence - A review of pathophysiology and treatment strategies for voiding dysfunction in men. Aust Fam Physician. 2017 Sep;46(9):661-666. [PubMed: 28892597]

4.

Thomas-White KJ, Hilt EE, Fok C, Pearce MM, Mueller ER, Kliethermes S, Jacobs K, Zilliox MJ, Brincat C, Price TK, Kuffel G, Schreckenberger P, Gai X, Brubaker L, Wolfe AJ. Incontinence medication response relates to the female urinary microbiota. Int Urogynecol J. 2016 May;27(5):723-33. [PMC free article: PMC5119460] [PubMed: 26423260]

5.

Pearce MM, Hilt EE, Rosenfeld AB, Zilliox MJ, Thomas-White K, Fok C, Kliethermes S, Schreckenberger PC, Brubaker L, Gai X, Wolfe AJ. The female urinary microbiome: a comparison of women with and without urgency urinary incontinence. mBio. 2014 Jul 08;5(4):e01283-14. [PMC free article: PMC4161260] [PubMed: 25006228]

6.

Taweel WA, Seyam R. Neurogenic bladder in spinal cord injury patients. Res Rep Urol. 2015;7:85-99. [PMC free article: PMC4467746] [PubMed: 26090342]

7.

Nygaard I. Clinical practice. Idiopathic urgency urinary incontinence. N Engl J Med. 2010 Sep 16;363(12):1156-62. [PubMed: 20843250]

8.

Aoki Y, Brown HW, Brubaker L, Cornu JN, Daly JO, Cartwright R. Urinary incontinence in women. Nat Rev Dis Primers. 2017 Jul 06;3:17042. [PMC free article: PMC5878864] [PubMed: 28681849]

9.

Reid G, Burton JP. Urinary incontinence: Making sense of the urinary microbiota in clinical urology. Nat Rev Urol. 2016 Oct;13(10):567-8. [PubMed: 27644934]

10.

Minassian VA, Drutz HP, Al-Badr A. Urinary incontinence as a worldwide problem. Int J Gynaecol Obstet. 2003 Sep;82(3):327-38. [PubMed: 14499979]

11.

Minassian VA, Stewart WF, Wood GC. Urinary incontinence in women: variation in prevalence estimates and risk factors. Obstet Gynecol. 2008 Feb;111(2 Pt 1):324-31. [PubMed: 18238969]

12.

Ebbesen MH, Hunskaar S, Rortveit G, Hannestad YS. Prevalence, incidence and remission of urinary incontinence in women: longitudinal data from the Norwegian HUNT study (EPINCONT). BMC Urol. 2013 May 30;13:27. [PMC free article: PMC3674916] [PubMed: 23721491]

13.

Brown JS, Seeley DG, Fong J, Black DM, Ensrud KE, Grady D. Urinary incontinence in older women: who is at risk? Study of Osteoporotic Fractures Research Group. Obstet Gynecol. 1996 May;87(5 Pt 1):715-21. [PubMed: 8677073]

14.

Hunskaar S, Lose G, Sykes D, Voss S. The prevalence of urinary incontinence in women in four European countries. BJU Int. 2004 Feb;93(3):324-30. [PubMed: 14764130]

15.

Nitti VW. The prevalence of urinary incontinence. Rev Urol. 2001;3 Suppl 1(Suppl 1):S2-6. [PMC free article: PMC1476070] [PubMed: 16985992]

16.

Sandvik H, Hunskaar S, Seim A, Hermstad R, Vanvik A, Bratt H. Validation of a severity index in female urinary incontinence and its implementation in an epidemiological survey. J Epidemiol Community Health. 1993 Dec;47(6):497-9. [PMC free article: PMC1059866] [PubMed: 8120507]

17.

Willis-Gray MG, Dieter AA, Geller EJ. Evaluation and management of overactive bladder: strategies for optimizing care. Res Rep Urol. 2016;8:113-22. [PMC free article: PMC4968994] [PubMed: 27556018]

18.

Sharma N, Chakrabarti S. Clinical Evaluation of Urinary Incontinence. J Midlife Health. 2018 Apr-Jun;9(2):55-64. [PMC free article: PMC6006804] [PubMed: 29962803]

19.

Hu JS, Pierre EF. Urinary Incontinence in Women: Evaluation and Management. Am Fam Physician. 2019 Sep 15;100(6):339-348. [PubMed: 31524367]

20.

Barber MD, Walters MD, Bump RC. Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7). Am J Obstet Gynecol. 2005 Jul;193(1):103-13. [PubMed: 16021067]

21.

Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, Yamanishi T, Yamaguchi O, Takeda M, Nishizawa O. Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. Urology. 2006 Aug;68(2):318-23. [PubMed: 16904444]

22.

Nygaard I, Holcomb R. Reproducibility of the seven-day voiding diary in women with stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2000;11(1):15-7. [PubMed: 10738929]

23.

Abdul-Rahman A, Al-Hayek S, Belal M. Urodynamic studies in the evaluation of the older man with lower urinary tract symptoms: when, which ones, and what to do with the results. Ther Adv Urol. 2010 Oct;2(5-06):187-94. [PMC free article: PMC3126081] [PubMed: 21789074]

24.

Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012 Jan 18;1:CD005429. [PubMed: 22258963]

25.

Balk E, Adam GP, Kimmel H, Rofeberg V, Saeed I, Jeppson P, Trikalinos T. Nonsurgical Treatments for Urinary Incontinence in Women: A Systematic Review Update [Internet]. Agency for Healthcare Research and Quality (US); Rockville (MD): Aug, 2018. [PubMed: 30516945]

26.

Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014 Jan;33(1):17-30. [PubMed: 24127366]

27.

Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, Newgreen D, Paireddy A, van Maanen R, Ridder A. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015 Mar;67(3):577-88. [PubMed: 24612659]

28.

Pratt TS, Suskind AM. Management of Overactive Bladder in Older Women. Curr Urol Rep. 2018 Sep 10;19(11):92. [PMC free article: PMC6666408] [PubMed: 30203368]

29.

Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary Incontinence in Women: A Review. JAMA. 2017 Oct 24;318(16):1592-1604. [PubMed: 29067433]

Disclosure: Shami Nandy declares no relevant financial relationships with ineligible companies.

Disclosure: Sudha Ranganathan declares no relevant financial relationships with ineligible companies.